Economic Burden of Drug Therapy in Hypertension Management in a Private Teaching Hospital in Nigeria

Ganiyu, Kehinde A.

doi:10.9734/bjpr/2014/3983

Cited by 4 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation has been documented in Nigeria 7,8. Overall, cost saving without loss of control is desirable and has prompted trial of single pill combination 9.…”

Section: Discussionmentioning

confidence: 88%

Economic benefit of back titration in the treatment of hypertension in Jos, Nigeria

Okeahialam¹,

Adeniyi

2017

CEOR

View full text Add to dashboard Cite

PurposeTreatment of hypertension is expensive and cost is one of the reasons for inadequate blood pressure control. Where there are no social cost cushions, the burden is borne by patients. With pervasive poverty and inadequate control, complications are unchecked. Back titration in appropriate circumstances should, therefore, translate to economic benefit. This is an attempt to compute, in economic terms, the benefit of back titration.Patients and methodsThirty-nine patients who entered an antihypertensive back titration program for 12 months and who had been earlier reported on, form the subject of this study. A survey of the cost of antihypertensives in pharmacy outlets in Jos, Nigeria was undertaken. Regimens of antihypertensives that patients were on at the onset and end of the 12 months of back titration were costed in Nigerian currency and compared.ResultsBack titration translated to economic benefit in all patients with a cost reduction varying from 2.3% to 100%. This reflected in reduction in mean daily cost of treatment of N107.09–N54.61.ConclusionThe benefit of antihypertensive back titration apart from psychological relief of lower pill burden and side effect profile is in pharmacoeconomics. This permits greater adherence and prevents morbi-mortality consequences of hypertension. In this study, back titration over 12 months translated to average cost reduction of >50%, making treatment more affordable. In appropriate circumstances, back titration of antihypertensives results in economic relief for patients. This should improve adherence, reduce morbi-mortality and is recommended for wider application.

show abstract

“…This observation has been documented in Nigeria 7,8. Overall, cost saving without loss of control is desirable and has prompted trial of single pill combination 9.…”

Section: Discussionmentioning

confidence: 88%

Economic benefit of back titration in the treatment of hypertension in Jos, Nigeria

Okeahialam¹,

Adeniyi

2017

CEOR

View full text Add to dashboard Cite

show abstract

“…This figure indicated high poverty rate among the patients with hypertension and diabetes in Ilorin, Nigeria. It also reflected the poverty index rate of the country where over 70% of its population lives on less than $1 per day 20,21 . Hypertension and DM run chronic courses therefore people living with these diseases have to be on medical treatment for a lifetime 5 .…”

Section: Discussionmentioning

confidence: 99%

“…The health insurance scheme program among the patients in the study area is predominantly Nigerian National Health Insurance Scheme (NHIS). This scheme was established as a social security system where the health care of the employees in the formal setting is paid for by a pooled contribution from the employee and employer 21 . While OOP expenditure and family supports still remained the commonest health financing options in Nigeria, health insurance scheme remains the best option for patients with hypertension and diabetes.…”

Section: Discussionmentioning

confidence: 99%

“…While OOP expenditure and family supports still remained the commonest health financing options in Nigeria, health insurance scheme remains the best option for patients with hypertension and diabetes. There is requirement for a steady and sustainable source of fund 21 in the management of hypertension and diabetes which OOP and family sources may not be able to sustain.…”

Section: Discussionmentioning

confidence: 99%

“…The direct cost predictors were drugs, transport cost and laboratory cost. Expectedly, drug has been established as a major driver of cost of care of cardiovascular disease in Nigeria 15,16,20,21 . This study also reported the importance of transport and laboratory costs in the follow-up care of patients with hypertension and diabetes in Nigeria.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Predictors of Cost of Follow-up Care among Patients with Hypertension and Diabetes Mellitus Attending a Teaching Hospital, North Central, Nigeria

Bolarinwa

Abdulahi

Sanya

et al. 2018

Journal of Health Science Research

View full text Add to dashboard Cite

Background: In sub-Saharan Africa, hypertension and diabetes mellitus (type II) remain major causes of cardiovascular disease. The prevalence of hypertension and diabetes remain high in Nigeria while the initial and follow-up management are almost entirely hospital-based. This constitutes huge financial burden not only to the patients, care givers and families, but also to the health system and the government. Information on basic cost of care of hypertension and diabetes and of those having both diseases as co-morbidities is still scanty in Nigeria. There is need to study the factors that strongly determine cost of follow-up care among this group of patients. Methodology: This study is a hospital-based cross-sectional study of 1,203 hypertensive and diabetic patients attending general and medical outpatient clinics of a teaching hospital in Nigeria. Results: The patients spend N6,401 ($32.16) on the average whenever they attend follow-up clinic. Close to threequarter (71.3%) of the patients spent more than 30 minutes to access follow-up clinic while similar proportion (74.3%) spent more than an hour waiting to be seen at the clinics. Major predictors of cost of follow-up care among hypertensive and Diabetics were; Drug, transportation and laboratory costs. Other predictors were; Male gender, long waiting time, accompanies persons; and co-morbidity of hypertension and diabetes. Conclusion: This study recommended that strategies that will reduce the cost of drugs, laboratory tests, and reducing waiting time will reduce the cost of managing hypertension and diabetes in Nigeria.

show abstract

Auditing the Cost of Treating Hypertension in a Tertiary Health Facility in Yobe State, North-Eastern Nigeria

Balami,

Baba

2024

Qeios

View full text Add to dashboard Cite

BACKGROUND: Studies quantifying the financial burden of hypertension are lacking, despite the high prevalence of this disease among Nigerian adults, together with its huge associated costs. AIM: The aim of this study was to estimate the cost of hypertension treatment and blood pressure control among patients attending a tertiary health centre in Yobe, Nigeria METHODS: The study utilised a cross-sectional study design, using interviewer-administered questionnaire to collect information from the respondents. Data on the cost of medications and laboratory investigations were collected from the hospital’s billing unit, while other costs were based on self-reporting by the patients. Overall cost of blood pressure control as well as cost-effectiveness for the different drug combinations were calculated. RESULTS: Most of the respondents were unemployed (62.2%), and out of those who were employed, 43.9% earned below the Nigerian minimum wage of ₦18,000. About a third (36.62%) of the respondents had their blood pressures controlled. The overall average cost of treating hypertension per patient per month was ₦3,374.00; and was ₦3,474.00 for those who were employed, for whom it corresponded to 12% of their monthly income. The average cost of achieving one blood pressure was ₦9,082.14. Mono-therapy with thiazide diuretics was the most cost-effective treatment option. CONCLUSION: The cost of treating hypertension in this study was on the high side, with a sub-optimal level of blood pressure control. Considering the high rate of unemployment, as well as the low income among those who were employed, there is the need for government to subsidise hypertension treatment.

show abstract

Economic Burden of Drug Therapy in Hypertension Management in a Private Teaching Hospital in Nigeria

Cited by 4 publications

References 9 publications

Economic benefit of back titration in the treatment of hypertension in Jos, Nigeria

Economic benefit of back titration in the treatment of hypertension in Jos, Nigeria

Predictors of Cost of Follow-up Care among Patients with Hypertension and Diabetes Mellitus Attending a Teaching Hospital, North Central, Nigeria

Auditing the Cost of Treating Hypertension in a Tertiary Health Facility in Yobe State, North-Eastern Nigeria

Contact Info

Product

Resources

About